Misfolded disease-associated protein

Misfolded disease-associated protein" is a generic, non-canonical term that does not refer to a specific protein or standardized drug target. Instead, it is used as an umbrella label for any protein whose incorrect three-dimensional folding leads to pathological protein aggregates implicated in various diseases[1][2][3][5]. Well-known examples include amyloid-beta in Alzheimer's disease, alpha-synuclein in Parkinson's disease, huntingtin in Huntington's disease, prion protein in prion diseases, islet amyloid polypeptide in type 2 diabetes, and others[2][3][5][7]. These misfolded proteins are central to a class of disorders known as proteinopathies or protein misfolding diseases, where accumulation of insoluble aggregates (often with beta-sheet-rich secondary structure) leads to cellular dysfunction and tissue degeneration[1][3][5][7]. The term does not designate a unique molecular entity and cannot be mapped to a single canonical "receptor" or "drug target" according to established nomenclature[1][3]. Targeted therapeutic development focuses on individual misfolded proteins relevant to each disease, not the generic concept. Summary of issues: - The query refers to a class of pathogenic protein forms, not a single molecular drug target[1][3]. - "Misfolded disease-associated protein" is not a recognized canonical name, abbreviation, or entity in drug target databases and is too nonspecific for structured scientific data extraction[2][3][5]. - While individual misfolded proteins (e.g., amyloid-beta, prion protein) are legitimate drug targets, the class as a whole is not directly targetable—therapies must focus on specific disease-related misfolded proteins[3][5]. Therefore, "Misfolded disease-associated protein" should not be used as a canonical drug target entry. Structured information should instead reference specific misfolded proteins by their full names and gene/protein symbols as indicated in the disease context.

Other names

Misfolded proteinProtein aggregateDisease-associated misfolded proteinMisfolded pathological proteinProteinopathy-related misfolded protein

Inhibition of protein aggregation; Clearance of protein aggregates (e.g., immunotherapy); Stabilization of native protein structure; Disruption of toxic oligomer formation; Antibody-mediated neutralization of aggregate toxicity